Antibody Information

General Information of This Antibody
Antibody ID
ANI0YTKVC
Antibody Name
Rosopatamab
Organization
Weill Cornell Medical
Indication
Prostate cancer
Synonyms
J-591; MLN-591; huJ-591; HUJ-591; HUJ591-GS; J591
   Click to Show/Hide
Antibody Type
Monoclonal antibody (mAb)
Antibody Subtype
Chimeric IgG1-kappa
Antigen Name
Glutamate carboxypeptidase 2 (FOLH1)
  Antigen Info 
ChEMBI ID
CHEMBL2109549
Click to Show/Hide the Sequence Information of This Antibody
Heavy Chain Sequence
EVQLVQSGPEVKKPGATVKISCKTSGYTFTEYTIHWVKQAPGKGLEWIGNINPNNGGTTY
NQKFEDKATLTVDKSTDTAYMELSSLRSEDTAVYYCAAGWNFDYWGQGTLLTVSSASTKG
PSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSL
SSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFL
FPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRV
VSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQ
VSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNV
FSCSVMHEALHNHYTQKSLSLSPGK
    Click to Show/Hide
Heavy Chain Varible Domain
EVQLVQSGPEVKKPGATVKISCKTSGYTFTEYTIHWVKQAPGKGLEWIGNINPNNGGTTY
NQKFEDKATLTVDKSTDTAYMELSSLRSEDTAVYYCAAGWNFDYWGQGTLLTVSS
    Click to Show/Hide
Heavy Chain Constant Domain 1
ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSS
GLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKV
    Click to Show/Hide
Heavy Chain Constant Domain 2
APELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTK
PREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAK
    Click to Show/Hide
Heavy Chain Constant Domain 3
GQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDS
DGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK
    Click to Show/Hide
Heavy Chain Hinge Region
EPKSCDKTHTCPPCP
    Click to Show/Hide
Heavy Chain CDR 1
GYTFTEYT
    Click to Show/Hide
Heavy Chain CDR 2
INPNNGGT
    Click to Show/Hide
Heavy Chain CDR 3
AAGWNFDY
    Click to Show/Hide
Light Chain Sequence
DIQMTQSPSSLSTSVGDRVTLTCKASQDVGTAVDWYQQKPGPSPKLLIYWASTRHTGIPS
RFSGSGSGTDFTLTISSLQPEDFADYYCQQYNSYPLTFGPGTKVDIKRTVAAPSVFIFPP
SDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLT
LSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
    Click to Show/Hide
Light Chain Varible Domain
DIQMTQSPSSLSTSVGDRVTLTCKASQDVGTAVDWYQQKPGPSPKLLIYWASTRHTGIPS
RFSGSGSGTDFTLTISSLQPEDFADYYCQQYNSYPLTFGPGTKVDIK
    Click to Show/Hide
Light Chain Constant Domain
RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD
SKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
    Click to Show/Hide
Light Chain CDR 1
QDVGTA
    Click to Show/Hide
Light Chain CDR 2
WAS
    Click to Show/Hide
Light Chain CDR 3
QQYNSYPLT
    Click to Show/Hide
Each Antibody-drug Conjugate Related to This Antibody
Full Information of The Activity Data of The ADC(s) Related to This Antibody
Rosopatamab tetraxetan [Clinical candidate]
 ADC Info 
Identified from the Human Clinical Data
Click To Hide/Show 3 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Efficacy Data Objective Response Rate (ORR)
9.38% (breast cancer)
0.00% (gastric cancer)
Patients Enrolled
Unresectable, locally advanced or metastatic breast cancer or gastric cancer refractory to standard therapy.
Administration Dosage
Intravenously over 60 to 90 minutes at 0.05, 0.10, 0.20, 0.30, 0.40, 0.50, 0.60, 0.75, or 0.90 mg/kg every 3 weeks.
Related Clinical Trial
NCT Number NCT02576548  Clinical Status Phase 1
Clinical Description
A phase 1/2 multicenter, open-label, dose-escalation, and dose-expansion study to evaluate the safety, pharmacokinetics, immunogencity, and antitumor activity of MEDI4276 in subjects with select HER2-expressing advanced solid tumors.
Primary Endpoint
In patients with breast cancer,ORR=9.38% (N=3/32),DOR=4.20-10.20 months. In the 0.05 to 0.40 mg/kg cohort,PFS=1.3-2.0 months. In the 0.50 to 0.75 mg/kg cohort,PFS=4.60-15.40 months. median overall survival (OS)=19.10 months (range 0.80-30.60, 95% CI 9.6-NA).
Other Endpoint
No objective responses in patients with gastric cancer,median PFS=1.80 months (range 0-10.7, 95% CI,1.3-3.0),median OS=6.50 months (range 2.80-16.30, 95% CI, 3.10-16.30).
Experiment 2 Reporting the Activity Date of This ADC [2]
Related Clinical Trial
NCT Number NCT00070837  Clinical Status Phase 1
Clinical Description
A phase 1/2 dose escalation trial of multiple doses of mLN2704 (DM1 conjugated monoclonal antibody mLN591) in subjects with metastatic androgen-independent prostate cancer.
Experiment 3 Reporting the Activity Date of This ADC [3]
Related Clinical Trial
NCT Number NCT00052000  Clinical Status Phase 1
Clinical Description
Phase 1 dose-escalation study of intravenous CMD-193 in subjects with advanced malignant solid tumors.
References
Ref 1 First-in-Human, Phase 1 Dose-Escalation Study of Biparatopic Anti-HER2 Antibody-Drug Conjugate MEDI4276 in Patients with HER2-positive Advanced Breast or Gastric Cancer. Mol Cancer Ther. 2021 Aug;20(8):1442-1453.
Ref 2 Phase 1/2 multiple ascending dose trial of the prostate-specific membrane antigen-targeted antibody drug conjugate MLN2704 in metastatic castration-resistant prostate cancer. Urol Oncol. 2016 Dec;34(12):530.e15-530.e21.
Ref 3 A Trial of MLN2704 in Subjects With Metastatic Androgen Independent Prostate Cancer; NCT00052000

If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.